These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 35597299)

  • 1. Mutations in DNA binding domain of p53 impede RSL1D1-p53 interaction to escape from degradation in human colorectal cancer cells.
    Ding L; Zhao C; Xu Y; Zhang Z; Nie Y; Liao K; Chen Y; Tu B; Zhang X
    Exp Cell Res; 2022 Aug; 417(1):113211. PubMed ID: 35597299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ribosomal L1 domain-containing protein 1 coordinates with HDM2 to negatively regulate p53 in human colorectal Cancer cells.
    Ding L; Zhang Z; Zhao C; Chen L; Chen Z; Zhang J; Liu Y; Nie Y; He Y; Liao K; Zhang X
    J Exp Clin Cancer Res; 2021 Aug; 40(1):245. PubMed ID: 34362424
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RSL1D1 promotes the progression of colorectal cancer through RAN-mediated autophagy suppression.
    Liu X; Chen J; Long X; Lan J; Liu X; Zhou M; Zhang S; Zhou J
    Cell Death Dis; 2022 Jan; 13(1):43. PubMed ID: 35013134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. P53-R273H mutation enhances colorectal cancer stemness through regulating specific lncRNAs.
    Zhao Y; Li Y; Sheng J; Wu F; Li K; Huang R; Wang X; Jiao T; Guan X; Lu Y; Chen X; Luo Z; Zhou Y; Hu H; Liu W; Du B; Miao S; Cai J; Wang L; Zhao H; Ying J; Bi X; Song W
    J Exp Clin Cancer Res; 2019 Aug; 38(1):379. PubMed ID: 31455383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential effect of plakoglobin in restoring the tumor suppressor activities of p53-R273H vs. p53-R175H mutants.
    Lo CS; Alavi P; Bassey-Archibong B; Jahroudi N; Pasdar M
    PLoS One; 2024; 19(10):e0306705. PubMed ID: 39361615
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Common cancer mutations R175H and R273H drive the p53 DNA-binding domain towards aggregation-prone conformations.
    Li L; Li X; Tang Y; Lao Z; Lei J; Wei G
    Phys Chem Chem Phys; 2020 May; 22(17):9225-9232. PubMed ID: 32307496
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Butein inhibits cancer cell growth by rescuing the wild-type thermal stability of mutant p53.
    Song B; Wang J; Ren Y; Su Y; Geng X; Yang F; Wang H; Zhang J
    Biomed Pharmacother; 2023 Jul; 163():114773. PubMed ID: 37156116
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SCH529074, a small molecule activator of mutant p53, which binds p53 DNA binding domain (DBD), restores growth-suppressive function to mutant p53 and interrupts HDM2-mediated ubiquitination of wild type p53.
    Demma M; Maxwell E; Ramos R; Liang L; Li C; Hesk D; Rossman R; Mallams A; Doll R; Liu M; Seidel-Dugan C; Bishop WR; Dasmahapatra B
    J Biol Chem; 2010 Apr; 285(14):10198-212. PubMed ID: 20124408
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Programmed cell death 11 modulates but not entirely relies on p53-HDM2 loop to facilitate G2/M transition in colorectal cancer cells.
    Ding L; Xu Y; Xu L; Zhao C; Zhang Z; Zhang J; Liao K; Chen Y; Li J; Mei X; Zhang X
    Oncogenesis; 2023 Dec; 12(1):57. PubMed ID: 38062028
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of functional domains necessary for mutant p53 gain of function.
    Yan W; Chen X
    J Biol Chem; 2010 May; 285(19):14229-38. PubMed ID: 20212049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The activating transcription factor 3 protein suppresses the oncogenic function of mutant p53 proteins.
    Wei S; Wang H; Lu C; Malmut S; Zhang J; Ren S; Yu G; Wang W; Tang DD; Yan C
    J Biol Chem; 2014 Mar; 289(13):8947-59. PubMed ID: 24554706
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of Compound Kushen Injection and cisplatin shows synergistic antitumor activity in p53-R273H/P309S mutant colorectal cancer cells through inducing apoptosis.
    Wu X; Lu Y; Qin X
    J Ethnopharmacol; 2022 Jan; 283():114690. PubMed ID: 34597653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of glucosylceramide synthase eliminates the oncogenic function of p53 R273H mutant in the epithelial-mesenchymal transition and induced pluripotency of colon cancer cells.
    Hosain SB; Khiste SK; Uddin MB; Vorubindi V; Ingram C; Zhang S; Hill RA; Gu X; Liu YY
    Oncotarget; 2016 Sep; 7(37):60575-60592. PubMed ID: 27517620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural basis of restoring sequence-specific DNA binding and transactivation to mutant p53 by suppressor mutations.
    Suad O; Rozenberg H; Brosh R; Diskin-Posner Y; Kessler N; Shimon LJ; Frolow F; Liran A; Rotter V; Shakked Z
    J Mol Biol; 2009 Jan; 385(1):249-65. PubMed ID: 18996393
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elevated expression of p53 gain-of-function mutation R175H in endometrial cancer cells can increase the invasive phenotypes by activation of the EGFR/PI3K/AKT pathway.
    Dong P; Xu Z; Jia N; Li D; Feng Y
    Mol Cancer; 2009 Nov; 8():103. PubMed ID: 19917135
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A common gain of function of p53 cancer mutants in inducing genetic instability.
    Liu DP; Song H; Xu Y
    Oncogene; 2010 Feb; 29(7):949-56. PubMed ID: 19881536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Butyrate supplementation regulates expression of chromosome segregation 1‑like protein to reverse the genetic distortion caused by p53 mutations in colorectal cancer.
    Chang CC; Kao WY; Liu CY; Su HH; Kan YA; Lin PY; Ku WC; Chang KW; Yang RN; Huang CJ
    Int J Oncol; 2022 Jun; 60(6):. PubMed ID: 35417036
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutant p53R273H attenuates the expression of phase 2 detoxifying enzymes and promotes the survival of cells with high levels of reactive oxygen species.
    Kalo E; Kogan-Sakin I; Solomon H; Bar-Nathan E; Shay M; Shetzer Y; Dekel E; Goldfinger N; Buganim Y; Stambolsky P; Goldstein I; Madar S; Rotter V
    J Cell Sci; 2012 Nov; 125(Pt 22):5578-86. PubMed ID: 22899716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer-associated mutations in the MDM2 zinc finger domain disrupt ribosomal protein interaction and attenuate MDM2-induced p53 degradation.
    Lindström MS; Jin A; Deisenroth C; White Wolf G; Zhang Y
    Mol Cell Biol; 2007 Feb; 27(3):1056-68. PubMed ID: 17116689
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutant p53-R273H mediates cancer cell survival and anoikis resistance through AKT-dependent suppression of BCL2-modifying factor (BMF).
    Tan BS; Tiong KH; Choo HL; Chung FF; Hii LW; Tan SH; Yap IK; Pani S; Khor NT; Wong SF; Rosli R; Cheong SK; Leong CO
    Cell Death Dis; 2015 Jul; 6(7):e1826. PubMed ID: 26181206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.